Influenza oseltamivir development

The neuramidase inhibitor oseltamivir phosphate was discovered by Gilead Sciences and developed by Roche Pharmaceuticals under the name of Tamiflu (Scheme 5.13) to be used as an orally active antiviral compound for prevention and treatment of influenza infections. Because of the recent emergence of the avian flu, the demand for Tamiflu has gained momentum. Two industrially feasible syntheses are known, starting from (—)-shikimic acid and (—)-quinic acid, respectively (Scheme 5.13) [45]. 

S. Abrecht, P. Harrington, H. Iding, M. Karpf, R. Trussardi, B. Wirz, and U. Zutter, The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu) A challenge for synthesis process research, Chimia, 58 (2004) 621-929. 

Lew, W. et al. Discovery and Development of GS 4104 (Oseltamivir) an Orally Active Influenza Neuraminidase Inhibitor. 2000 [63a]... 

Lew, W., Chen, X. and Kim, C.U. (2000) Discovery and development of GS 4104 (oseltamivir) an orally active influenza neuraminidase inhibitor. Current Medicinal Chemistry, 7, 663-672. 

Oseltamivir phosphate (Tamiflu ) was developed for the treatment and prevention of influenza virus infections. The key starting material of one commercial route is... 

In pursuit of a rapid and cost-effective synthesis of the anti-influenza drug (—)-oseltamivir (83) (Tamiflu , as phosphate), Hayashi and coworkers have developed an innovative synthesis involving three one-pot processes (Scheme 7.15) [56]. A large-scale synthesis of Tamiflu is considered so profoundly important today with... 

---